Apex Healthcare Bhd has been gaining traction recently. The counter was on the top gainers’ list on April 1, up 3.4% to close at RM3.05. It is certainly no April’s Fool’s joke as the counter has been climbing despite being given stock downgrades by analysts.
On a year-to-date basis, the pharmaceutical company has risen 22% having touched a 52-week high of RM3.16 from a low of RM2.34 In February, it posted a record FY23 revenue with special dividend of 20 sen, which probably got investors excited.
However, analysts are less positive on Apex Healthcare. Apex’s 4QFY23 core earnings fell 40% on a YoY basis, despite posting a 9% revenue growth. It was dragged by several factors including lower contribution from 16%-owned Straits Apex as a result of reduced equity stake and higher amortisation expenses as well as higher tax expenses.
Straits Apex is an orthopaedic business, which Apex Healthcare pare its stake from 40% to 16% in May 2023. Even as Covid cases are on the rise, Xepa anticipates that demand for flu-related medication in 4QCY23 will not increase materially, possibly due to milder symptoms. As a result, revenue and earnings could be lower QoQ given demand for pharmaceutical products (especially flu-related medications) could experience moderation.
In FY24, Apex Healthcare is expected to register a 7% revenue growth albeit a flattish earnings growth following the lower effective equity stake in SA. Moving forward, Apex plans to submit applications to relevant authorities this year for the expansion of warehouses and liquid production facilities in a newly acquired 20.7-acre land.
However, the earnings contribution from this initiative may materialise only after 2025. After that, further upside will be supported by an organic expansion pipeline, given that the Cheng Industrial Estate production facility in Melaka is fully utilise
The stock is also likely to see higher FY23-25 earnings banking on Xepa-Soul Pattinson (Malaysia)’s (Xepa) long-term expansion plans. Xepa is involved in the development, manufacturing and marketing of off-patent/generic pharmaceutical products and medical devices. The Xepa campus is situated in Cheng Industrial Estate, Melaka, encompassing a 10-acre site.
Analysts anticipate Apex Healthcare’s FY26 earnings to register a 8.5% YoY growth, underpinned by an ageing population, public health education advancement and continuously expanding healthcare expenditure.
Created by zaclim | Aug 29, 2024
AirAsia X Bhd is still not out of the woods but is seeing a rebound after its share price rose to a high of RM1.35 recently. Can it continue to fly higher?
Created by zaclim | Aug 28, 2024
Cuscapi Bhd has gained 50% in terms of value year-to-date and signs indicate that the good run still has legs.
Created by zaclim | Aug 27, 2024
After a turnaround in its financials, Pesona Metro Holdings Bhd has been attracting investors’ interest especially after bagging 4 contracts in a year. Will its good run in share price be sustainable?
Created by zaclim | Aug 26, 2024
Able Global Bhd has been surging in recent weeks although still shy of its 52-week high seen in June. Will the counter be able to reach its high?
Created by zaclim | Aug 26, 2024
Johor Plantations Group Bhd may not have performed as well as other listings this year but signs indicate the counter might trend higher
Created by zaclim | Aug 22, 2024
AEON Co. (M) Bhd is experiencing significant growth, with its stock hitting a 52-week high of RM1.54 on August 21, a 30% surge year-to-date. Can it continue to draw investors’ interest?
Created by zaclim | Aug 21, 2024
Capital A Bhd may be racing against time to get itself out of the PN17 status but its share price has been moving upwards. Can it maintain its positive run?
Created by zaclim | Aug 20, 2024
PBA has been making a big splash following the revisions on water tariff. This goes to enhance it bottomline and provide a catalyst for investors looking for exposure in this segment.
Created by zaclim | Aug 19, 2024
Vestland Bhd has been building a strong momentum after it dipped to its low of 30 sen in January. Can it continue to make a good run?
Created by zaclim | Aug 16, 2024
Investors should be happy that pole maker Mestron Holdings Bhds seeing a strong rise in its share price in the past 5 days, igniting hopes of sustained upward momentum